胰、胆疾病患者血清GLS含量测定

Determination of Serum Gangliosides in Patients with Pancreatic and Biliary Track Diseases

目的 研究胰、胆疾病患者血清GLS含量及其临床意义。方法 测定胰、胆癌症与非癌患者GLS含量 ,然后分组统计分析。结果 胰癌组GLS(973± 32 2mg/L)显著高于胰脏非癌组 (5 75± 2 18)和糖尿病组 (5 37± 87) ;胆道癌组GLS(90 8± 2 73)显著高于胆道非癌组 (5 2 1± 10 9)。该五组GLS阳性率 (>6 6 0mg/L)依次为 93.8%、2 6 .7%、4 .1%、85 .7%、9.3% ;胰、胆癌症组均显著高于非癌疾病组。结论 胰、胆癌症患者血清GLS显著增加 ;

Objective To study the quantities of serum gangliosides(GLS)and their clinical values in patients with pancreatic and biliary diseases. Methods The serum GLS of patients with pancreatic or biliary track cancers and non cancer diseases were determined,and a statistical analysis was given to each group. Results The serum GLS in pancreatic cancer group (973±322mg/L)were significantly higher than those in pancreatic non cancer group (575±218)and those in diabetes group (537±87);the serum GLS in biliary cancer group (908±273)were evidently higher than those in biliary track benign disease group (521±109).The positive ratio of GLS(>660mg/L)in the five groups were 93.8%,26.7%,4.1%,85.7% and 9.3% respectively;the cancer groups were increased significantly over other groups. Conclusions Serum GLS are remarkably increased in patients with pancreatic or biliary track cancer and it is of evident clinical values in diagnosis.